grant
Ultra-sensitive mass spectrometry-based immunopeptidomics using digital microfluidics.
NIHUS FederalResearch GrantFY2025AdoptionAmerican Lung AssociationAntibodiesAntigen PresentationAntigen-Presenting CellsAntineoplastic VaccineAutomationBiomedical ResearchBiopsyBispecific Monoclonal AntibodiesBody TissuesCAR T cellsCAR modified T cellsCAR-TCAR-TsCancer CauseCancer EtiologyCancer PatientCancer TreatmentCancer VaccinesCancersCell BodyCell IsolationCell SegregationCell SeparationCell Separation TechnologyCellsCessation of lifeCheckpoint inhibitorClinicalClinical OncologyCommunitiesComplexCoupledDeathDendritic CellsDevelopmentDevicesElectrodesFaceFutureHistocompatibility ComplexHistocompatibility ComplicesImmuneImmune EvasionImmune checkpoint inhibitorImmune mediated therapyImmune systemImmunesImmunologically Directed TherapyImmunooncologyImmunotherapeutic agentImmunotherapyIndividualInterventionLiquid ChromatographyLiquid substanceLung NeoplasmsLung TumorMHC ReceptorMacrophageMajor Histocompatibility ComplexMajor Histocompatibility Complex ReceptorMajor Histocompatibility ComplicesMalignant CellMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMalignant Tumor of the LungMalignant neoplasm of lungMapsMass Photometry/Spectrum AnalysisMass SpectrometryMass SpectroscopyMass SpectrumMass Spectrum AnalysesMass Spectrum AnalysisMeasurementMeasuresMethodsMicrofluidic DeviceMicrofluidic Lab-On-A-ChipMicrofluidic MicrochipsMicrofluidicsMiniaturisationsMiniaturizationMφNSCLCNSCLC - Non-Small Cell Lung CancerNeedlesNeoplasm VaccinesNon-Small Cell Lung CancerNon-Small-Cell Lung CarcinomaNormal CellPatientsPopulationPreparationPrimary NeoplasmPrimary TumorProceduresProcessProteomicsPulmonary CancerPulmonary NeoplasmsPulmonary malignant NeoplasmPumpReportingReproducibilitySamplingSpeedSurvival RateSystemT cells for CART-Cell Antigen ReceptorsT-Cell ReceptorT-CellsT-LymphocyteT-cell receptor repertoireTCR repertoireTechnologyTissuesTranslational ResearchTranslational ScienceTubeTumor AntigensTumor CellTumor TissueTumor VaccinesTumor-Associated AntigenTumor-Infiltrating LymphocytesVeiled Cellsaccessory cellanti-cancer immunotherapyanti-cancer researchanti-cancer therapyanti-tumor vaccineanticancer immunotherapybi-specific monoclonal antibodiescancer antigenscancer cellcancer immunotherapycancer microenvironmentcancer researchcancer therapycancer-directed therapycell sortingchemotherapychimeric antigen T cell receptorchimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cellschimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellscomputer chipdevelopmentaldigitaldigital platformexperimentexperimental researchexperimental studyexperimentsfacesfacialfightingfluidimmune check point inhibitorimmune drugsimmune evasiveimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based cancer therapiesimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmune-oncologyimmuno oncologyimmuno therapyimmunologic therapeuticsimmunology oncologyimmunotherapeuticsimmunotherapy agentimmunotherapy for cancerimmunotherapy of cancerimprovedindividualized cancer therapyinnovateinnovationinnovativeinsightliquidlung cancermagnetic beadsmalignancymass spectrometermicrochipmicrofluidic chipmicrofluidic technologynanoDropletneoplasm/cancerneoplastic celloncoimmunologypersonalized cancer therapypersonalized cancer treatmentpreparationsside effectspatial and temporalspatial temporalspatiotemporalsuccesssurfactantthymus derived lymphocytetooltranslation researchtranslational investigationtumortumor microenvironmenttumor-specific antigenvaccine for cancerµfluidicµfluidic technology
Description preview
PROJECT SUMMARY
The identification of Tumor-Specific Antigens (TSAs) is critical for developing effective cancer immunotherapies.
Mass spectrometry-based immunopeptidomics has emerged as a powerful tool for unbiased and systematic
identification of TSAs as physical molecules. However, current immunopeptidomics platforms face challenges in…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click